
    
      Evaluate the safety and tolerability of MEDI-563 in adults with atopic asthma; and evaluate
      the effects of MEDI-563 on eosinophil counts in airway mucosal biopsies 28 days after
      completion of dosing in adults with atopic asthma.
    
  